Ontology highlight
ABSTRACT:
SUBMITTER: Haibe-Kains B
PROVIDER: S-EPMC4608867 | biostudies-literature | 2013 Dec
REPOSITORIES: biostudies-literature
Haibe-Kains B B Desmedt C C Di Leo A A Azambuja E E Larsimont D D Selleslags J J Delaloge S S Duhem C C Kains J P JP Carly B B Maerevoet M M Vindevoghel A A Rouas G G Lallemand F F Durbecq V V Cardoso F F Salgado R R Rovere R R Bontempi G G Michiels S S Buyse M M Nogaret J M JM Qi Y Y Symmans F F Pusztai L L D'Hondt V V Piccart-Gebhart M M Sotiriou C C
Genomics data 20131001
Validated biomarkers predictive of response/resistance to anthracyclines in breast cancer are currently lacking. The neoadjuvant Trial of Principle (TOP) study, in which patients with estrogen receptor (ER)-negative tumors were treated with anthracycline (epirubicin) monotherapy, was specifically designed to evaluate the predictive value of topoisomerase II-alpha (TOP2A) and develop a gene expression signature to identify those patients who do not benefit from anthracyclines. Here we describe in ...[more]